By Dani Kass (January 29, 2018, 3:27 PM EST) -- Paul Hastings LLP convinced the U.S. Patent Trial and Appeal Board to invalidate a major patent covering AbbVie's $16 billion biologic Humira and uphold four patents covering an Acorda Therapeutics Inc. multiple sclerosis drug, landing the firm a spot among Law360's 2017 Life Sciences Groups of the Year.
The firm's patent practice, which life sciences Chair Bruce Wexler said has a 24-0 record at the PTAB, is complemented by a team of life sciences attorneys focused on privacy, cybersecurity, compliance, corporate work and mergers and acquisitions. Of the firm's 1,013 attorneys, 126 work on life sciences, largely in California, New York...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!